nor-Binaltorphimine (nor-BNI), kappa opioid receptor antagonist (ab120078)
Key features and details
- Potent and selective κ opioid receptor antagonist
- CAS Number: 105618-26-6
- Soluble in water to 50 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
nor-Binaltorphimine (nor-BNI), kappa opioid receptor antagonist -
Description
Potent and selective κ opioid receptor antagonist -
Alternative names
- nor-BNI
-
Biological description
Potent and selective κ opioid receptor antagonist
-
CAS Number
105618-26-6 -
Chemical structure
Properties
-
Chemical name
17,17'-(Dicyclopropylmethyl)-6,6',7,7'-6,6'-imino-7,7'-binorphinan-3,4',14,14'-tetrol dihydrochloride -
Molecular weight
734.72 -
Molecular formula
C40H43N3O6.2HCl -
PubChem identifier
11957626 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in water to 50 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1.Cl.Cl -
Source
Synthetic
-
Research areas
Images
-
Chemical Structure - nor-Binaltorphimine (nor-BNI), kappa opioid receptor antagonist (ab120078)2D chemical structure image of ab120078, nor-Binaltorphimine (nor-BNI), kappa opioid receptor antagonist
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (5)
ab120078 has been referenced in 5 publications.
- Makino Y et al. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Commun Biol 5:299 (2022). PubMed: 35365763
- He Y et al. Transgenic increase in the ß-endorphin concentration in cerebrospinal fluid alleviates morphine-primed relapse behavior through the µ opioid receptor in rats. J Med Virol 91:1158-1167 (2019). PubMed: 30701563
- Sun J et al. Salvinorin A attenuates early brain injury through PI3K/Akt pathway after subarachnoid hemorrhage in rat. Brain Res 1719:64-70 (2019). PubMed: 31125530
- Azocar VH et al. The blocking of kappa-opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization. J Neurochem 148:348-358 (2019). PubMed: 30315655
- Li TF et al. Ester Hydrolysis Differentially Reduces Aconitine-Induced Anti-hypersensitivity and Acute Neurotoxicity: Involvement of Spinal Microglial Dynorphin Expression and Implications for Aconitum Processing. Front Pharmacol 7:367 (2016). PubMed: 27761113